New ‘Broad-Spectrum’ Antiviral
Posted by SR in News, tags: antiviral, drug discovery, small molecule
LJ-001
Although LJ-001 also binds to cellular membranes, the team believe that its low toxicity can be attributed to the fact that metabolically active cells are able to repair their membranes whilst static viruses are not. LJ-001showed no overt toxicity at effective anti-viral concentrations in either in vitro or in vivo studies, and pretreatment of mice with LJ-001 prevented virus-induced mortality from Ebola and Rift Valley fever viruses.
The study is published in Proceedings of the National Academy of Sciences.
Related posts:
- Natural Antiviral Proteins Discovered Viruses are economical with their own genetic information, relying on requisition of host cellular proteins to complete their lifecycle. In...
- MS Drug Could Also Fight Viral Infections A drug that is being developed to treat multiple sclerosis (MS) by damping down the immune system may also have...
- Small Molecule Inhibitors of Kaposi’s Sarcoma Virus Protease Kaposi’s sarcoma (KS) is caused by Kaposi sarcoma herpes virus (KSHV) which is also known as human herpes virus 8...
- Targeting Influenza A Nucleoprotein Although the recent sporadic outbreaks of influenza A virus H5N1 and of a new variant of H1N1 in 2009 were...
- siRNA Experiments Identify Ebola Virus Drug Targets Antiviral drugs that exclusively target viral factors rather than host cell processes offer the possibility of fewer side effects but...
Related posts brought to you by Yet Another Related Posts Plugin.
This entry was posted on Wednesday, February 3rd, 2010 at 10:35 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.


















Entries (RSS)
Its good to see a “thiazolidinone derivative” as antiviral drug derivative. Azoles are already known as anttimicrobial agents and this is in addition